Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06507657
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sodium-glucose cotransporter 2 inhibitors SGLT2i reduce CVD events including incident HF SGLT2 is a glucose transport protein in the kidneys Inhibition of this protein results in glucosuria and lower serum blood sugar The SGLT2i medications were initially approved to treat type 2 diabetes T2D In 2015 Zinman et al published the first large randomized clinical trial RCT demonstrating a lower composite CVD outcome in adults with T2D treated with empagliflozin compared to placebo HR 085 95 CI 074-099 In the specific case of empagliflozin the hazard ratio was 075 95 CI 065-086 for HFrEF 8 and 079 95 CI 069-090 for HFpEF using a treatment dose of 10mg daily
The purpose of this placebo-controlled double-blinded randomized pilot study is to investigate the effect of empagliflozin on left atrial LA function in 80 patients who are at risk for heart failure Participants will be randomized 11 to either intake of a 10mg empagliflozin oral tablet or a matching placebo once daily
The purpose of this placebo-controlled double-blinded randomized pilot study is to investigate the effect of empagliflozin on left atrial LA function in 80 patients who are at risk for heart failure Participants will be randomized 11 to either intake of a 10mg empagliflozin oral tablet or a matching placebo once daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None